期刊文献+

生产企业在药品上市后风险管理中的重要作用 被引量:9

Role of Drug Manufacturers in Post- marketed Drug Risk Management
在线阅读 下载PDF
导出
摘要 通过借鉴欧美国家关于药品风险管理指导原则的主要内容以及ICH文件精神,提出了药品风险管理包括风险信息收集、风险识别、风险评估、风险管理以及风险管理措施的后效评估,强调药品生产企业应当在风险管理各环节切实履行企业责任。 According to the content of risk management guidances in EU and USA, and spirit of ICH document, this paper puts forward that drug risk management includes risk information collection, risk identification, risk evaluation, risk management and evaluation of the effectiveness on risk management measures. This paper also puts emphasis on the responsibility of drug manufacturers, which should be implemented on risk management.
出处 《中国药物警戒》 2014年第2期88-93,共6页 Chinese Journal of Pharmacovigilance
基金 "十二五"重大新药创制专项课题"大品种药物IV期临床试验及新药临床试验审评研究技术平台"(2011ZX09304-08)
关键词 药品 生产企业 风险管理 企业责任 drug drug manufacturers risk management responsibility of manufacturers
作者简介 任经天,男,副研究员,药品不良反应监测与评价。 通讯作者:商洪才,男,研究员,药品评价。E-mail:shanghongcai@126.com 通讯作者:杜晓曦,女,主任药师,药品不良反应监测与评价。E-mail:duxiaoxi@cdr.gov.cn
  • 相关文献

参考文献8

  • 1FDA. Guidance for Industry Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment[EB/OL].http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4136b1_02_Good%20Pharmacovigilance%20Practices.pdf,2014.
  • 2EMEA. Guideline on good pharmacovigilance practices(GVP) Module V-Risk management systems[EB/OL].http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129134.pdf,2014.
  • 3ICH. POST-APPROVAL SAFETY DATA MANAGEMENT:DEF-INITIONS AND STANDARDS FOR EXPEDITED REPORTING (ICH E2D)[EB/OL].http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2D/Step4/E2D_Guideline.pdf,2014.
  • 4ICH. PHARMACOVIGILANCE PLANNING (ICH E2E)[EB/OL].http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2E/Step4/E2E_Guideline.pdf,2014.
  • 5任经天,王胜锋,侯永芳,杜晓曦,李立明.常用药品不良反应信号检测方法介绍[J].中国药物警戒,2011,8(5):294-298. 被引量:80
  • 6Brian L.Strom. Pharmacoepidemiology 4th ed[M].West Sussex,England:John Wiley and Sons,Ltd,2005.
  • 7CFDA.中药注射剂风险管理计划指导原则(试行).
  • 8Prieto L,Spooner A,Hidalgo-Simon A. Evaluation of the effectiveness of risk minimization measures[J].Pharmacoepidemiology and Drug Safety,2012,(08):896-899.

二级参考文献14

  • 1Rawlins, M D. Spontaneous reporting of adverse drug reactions. I: the data[J]. Br J Clin Pharmacol, 1988,26(1): 1-5.
  • 2Rawlins, M D. Spontaneous reporting of adverse drug reactions. II: Uses[J]. Br J Clin Pharmacol, 1988,26(1): 7-11.
  • 3Finney, D J. The design and logic of a monitor of drug use [J].J Chronic Dis, 1965,18: 77-98.
  • 4Napke, E. Drug adverse reaction alerting program[J].Canad Pharm J, 1968,20:251-254.
  • 5Finney, D J Systematic signalling of adverse reactions to drugs[J]. Meth Inf Med, 1974,13: 1-10.
  • 6Napke, E. The Canadian drug adverse reaction reporting program [J]. Drug Inf J, 1975,9(2-3): 224-232.
  • 7Moore,N F Thiessard,B Begaud. The history of disproportionality measures (reporting odds ratio, proportional reporting rates) in spontaneous reporting of adverse drug reactions[J].Pharmacoepidemiol Drug Saf 2005,14(4): 285-286.
  • 8Hochberg, A M M Hauben, R K Pearson, et al. An evaluation of three signal-detection algorithms using a highly inclusive reference event database[J].Drug Saf,, 2009,32(6):509-525.
  • 9van Puijenbroek,E P A Bate, H G Leufkens, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions[J]. Pharmacoepidemiol Drag Saf, 2002,11(1): 3-10.
  • 10Kubota, K D Koide,T Hirai. Comparison of data mining methodologies using Japanese spontaneous reports[J]. Pharmacoepidemiol Drug Saf, 2004,13(6):387-394.

共引文献79

同被引文献70

引证文献9

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部